Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Receivables (2021 - 2023)

Relay Therapeutics (RLAY) has disclosed Change in Receivables for 3 consecutive years, with -$211000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Change in Receivables fell 424.62% to -$211000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$306000.0, a 215.46% decrease, with the full-year FY2023 number at -$306000.0, down 215.46% from a year prior.
  • Change in Receivables was -$211000.0 for Q4 2023 at Relay Therapeutics, down from $133000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $525000.0 in Q3 2021 to a low of -$75.0 million in Q1 2021.
  • A 3-year average of -$6.3 million and a median of -$33500.0 in 2022 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 382.98% in 2023; the steepest drop was 1194.74% in 2023.
  • Relay Therapeutics' Change in Receivables stood at -$401000.0 in 2021, then skyrocketed by 116.21% to $65000.0 in 2022, then plummeted by 424.62% to -$211000.0 in 2023.
  • Per Business Quant, the three most recent readings for RLAY's Change in Receivables are -$211000.0 (Q4 2023), $133000.0 (Q3 2023), and -$208000.0 (Q2 2023).